Navigation Links
Clue found to Epstein-Barr virus' ability to form and sustain tumors

Researchers at the University of Wisconsin School of Medicine and Public Health (SMPH) have found a viral target that opens the door for the development of drugs to destroy tumors caused by Epstein-Barr virus (EBV).

The finding, published in the Sept. 4 Proceedings of the National Academy of Sciences Online, identifies the activity of a critical segment of a viral protein required to sustain EBV-related tumors. The researchers found that when they blocked this activity, the virus life cycle was broken.

Often linked to infectious mononucleosis, EBV also causes cancers that kill 100,000 people around the world each year. The virus, which infects the immune system's B cells and causes them to grow, is directly responsible for Burkitt's lymphoma, an often-fatal malignancy affecting thousands of African children annually. It is also causally associated with at least four other kinds of human cancers, including Hodgkin's lymphomas, lymphomas in AIDS patients and organ transplant recipients as well as nasopharyngeal carcinomas.

The SMPH researchers, based at the McArdle Laboratory for Cancer Research, focused on a viral protein they had previously found to be necessary to keeping Burkitt's lymphoma cells alive and growing in culture. The protein, called Epstein-Barr nuclear antigen 1 (EBNA-1), is the only protein the virus makes in all EBV-positive tumors.

"We've been trying to identify specific functions of EBNA-1 that we could target therapeutically," says Bill Sugden, professor of oncology who has studied EBV for more than 30 years. "Our goal is to develop a successful anti-viral, anti-tumor therapy for all EBV-positive tumors."

In the current study, Sugden and his colleague of 20 years, Wolfgang Hammerschmidt, now based at the German National Research Center for Environment and Health, designed genetic experiments to mutate various segments of the 640 amino acids that make up the EBNA-1 protein, which is one of about 100 proteins EBV encodes. They then infected human B cells with EBVs carrying various mutant EBNA-1s.

The analysis showed that one 25-amino acid segment within EBNA-1 was responsible for the regulation of viral gene transcription, the first step in the process by which a gene's coded information is converted first into RNA and then into protein.

Mutating the unique segment of amino acids prevented EBNA-1 from transforming resting B cells into proliferating cells.

Under normal conditions, a cellular protein binds this 25-amino acid segment of EBNA-1, allowing transcription of viral and cellular genes regulated by EBNA-1 to occur. Hammerschmidt and Sugden are now trying to identify the cellular protein.

"If we can identify this protein, it will be easier for us to develop assays to screen for small molecules that will compete with the protein in binding to EBNA-1," Sugden says. "By preventing the cellular protein from binding with the segment, EBNA-1 will not be able to carry out its function and the tumor cells it sustains will die."

The goal, which Sugden expects is achievable, is to end up with a drug that kills only EBV-positive tumor cells and doesn't harm other tissues in the body.


Source:University of Wisconsin-Madison

Related biology news :

1. New component of the brakes on nerve regeneration found
2. Strongest proof yet found for prion hypothesis
3. A puzzle piece found in unraveling the wiring of the brain
4. New World founders small in number
5. Norovirus found to cause travelers diarrhea
6. Pair of cancer genes found to drive both cell migration and division
7. Alien woodwasp, threat to US pine trees, found in N.Y.
8. Achilles heel of the herpes virus possibly found
9. Purdue scientists may have found key to halting spinal cord damage
10. Unexpected lock and key mechanism found for the assembly of tumor blood vessels
11. New protein vital for immune response is found in surprise location
Post Your Comments:

(Date:10/6/2015)... 2015 Track Group, Inc. (OTCQX: TRCK), a ... signed a contract with the Virginia Department of Corrections ... of sentences under the Department,s oversight. Derek ... contract with the Virginia DOC will expand our footprint ... our position as a trusted leader in offender electronic ...
(Date:10/2/2015)... ) has ... Law Using Biometrics" report to their offering. ... addition of the "Enforcing the Law Using ... Research and Markets ( ) has ... Law Using Biometrics" report to their offering. ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  Generex Biotechnology Corporation ( ... into a non-binding Letter of Intent (LOI) with MediTemp Ltd. ... developed a proprietary cooling technology designed to improve sperm quality ... the United States and three million men in ... and 44 diagnosed as infertile.  For 42% of those men, ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... (HIFU) technologies, announced today that it received de novo clearance from the U.S. ... U.S. for the ablation of prostate tissue. Sonablate® is the first High Intensity ...
(Date:10/13/2015)... the United States , Canada ... all new cases of kidney cancer.   --> ... Europe .  PRCC represents about 14% of all ... MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma Limited ... completed enrolment in a global Phase II study of savolitinib (AZD6094), ...
(Date:10/12/2015)... MARIETTA, Ga. , Oct.12, 2015  MiMedx Group, ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and ... tam complaint which had been filed against the Company ... Parker H. Petit , Chairman and CEO, stated, "As ...
Breaking Biology Technology: